{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:37:49Z","timestamp":1780047469100,"version":"3.53.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00277-024-05898-3","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T10:01:58Z","timestamp":1721642518000},"page":"3535-3541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis"],"prefix":"10.1007","volume":"103","author":[{"given":"Keiki","family":"Nagaharu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Ohya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Edahiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideho","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki I.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuto","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohshi","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Tawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"5898_CR1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues, rev","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, rev, 4th edn. IARC, Lyon, France","edition":"4"},{"issue":"5","key":"5898_CR2","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057\u20131069. https:\/\/doi.org\/10.1038\/s41375-018-0077-1","journal-title":"Leukemia"},{"issue":"26","key":"5898_CR3","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T et al (2012) Development and validation of an International Prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128\u20135133 quiz 5252. https:\/\/doi.org\/10.1182\/blood-2012-07-444067","journal-title":"Blood"},{"issue":"11","key":"5898_CR4","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T et al (2015) Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 5(11):e369. https:\/\/doi.org\/10.1038\/bcj.2015.94","journal-title":"Blood Cancer J"},{"issue":"6","key":"5898_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761\u2013770. https:\/\/doi.org\/10.1200\/JCO.2010.31.8436","journal-title":"J Clin Oncol"},{"issue":"4","key":"5898_CR6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/j.seminhematol.2005.08.003","volume":"42","author":"A Tefferi","year":"2005","unstructured":"Tefferi A, Spivak JL (2005) Polycythemia vera: scientific advances and current practice. Semin Hematol 42(4):206\u2013220. https:\/\/doi.org\/10.1053\/j.seminhematol.2005.08.003","journal-title":"Semin Hematol"},{"issue":"5","key":"5898_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s12185-022-03412-x","volume":"116","author":"Y Edahiro","year":"2022","unstructured":"Edahiro Y et al (2022) Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study. Int J Hematol 116(5):696\u2013711. https:\/\/doi.org\/10.1007\/s12185-022-03412-x","journal-title":"Int J Hematol"},{"issue":"2","key":"5898_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s12185-021-03253-0","volume":"115","author":"Y Hashimoto","year":"2022","unstructured":"Hashimoto Y et al (2022) Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study. Int J Hematol 115(2):208\u2013221. https:\/\/doi.org\/10.1007\/s12185-021-03253-0","journal-title":"Int J Hematol"},{"issue":"2","key":"5898_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/bjh.12117","volume":"160","author":"G Bonicelli","year":"2013","unstructured":"Bonicelli G et al (2013) Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol 160(2):251\u2013254. https:\/\/doi.org\/10.1111\/bjh.12117","journal-title":"Br J Haematol"},{"issue":"9","key":"5898_CR10","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874\u20131881. https:\/\/doi.org\/10.1038\/leu.2013.163","journal-title":"Leukemia"},{"issue":"11","key":"5898_CR11","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","volume":"3","author":"A Carobbio","year":"2019","unstructured":"Carobbio A et al (2019) Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv 3(11):1729\u20131737. https:\/\/doi.org\/10.1182\/bloodadvances.2019000211","journal-title":"Blood Adv"},{"issue":"5","key":"5898_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/ajh.27261","volume":"99","author":"I Krecak","year":"2024","unstructured":"Krecak I et al (2024) The triple A model (age, absolute neutrophil count, absolute lymphocyte count-AAA) predicts survival and thrombosis in polycythemia vera. Am J Hematol 99(5):989\u2013992. https:\/\/doi.org\/10.1002\/ajh.27261","journal-title":"Am J Hematol"},{"issue":"4","key":"5898_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/life14040523","volume":"14","author":"M Lucijanic","year":"2024","unstructured":"Lucijanic M et al (2024) Evaluation of absolute neutrophil, lymphocyte and platelet count and their ratios as predictors of thrombotic risk in patients with prefibrotic and overt myelofibrosis. Life (Basel) 14(4):523. https:\/\/doi.org\/10.3390\/life14040523","journal-title":"Life (Basel)"},{"issue":"4","key":"5898_CR14","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","volume":"114","author":"T Barbui","year":"2009","unstructured":"Barbui T et al (2009) Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 114(4):759\u2013763. https:\/\/doi.org\/10.1182\/blood-2009-02-206797","journal-title":"Blood"},{"issue":"4","key":"5898_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.seminhematol.2005.05.023","volume":"42","author":"A Falanga","year":"2005","unstructured":"Falanga A et al (2005) Pathogenesis of thrombosis in essential thrombocythemia and polycythemia Vera: the role of neutrophils. Semin Hematol 42(4):239\u2013247. https:\/\/doi.org\/10.1053\/j.seminhematol.2005.05.023","journal-title":"Semin Hematol"},{"issue":"2","key":"5898_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41408-022-00625-5","volume":"12","author":"A Carobbio","year":"2022","unstructured":"Carobbio A et al (2022) Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer J 12(2):28. https:\/\/doi.org\/10.1038\/s41408-022-00625-5","journal-title":"Blood Cancer J"},{"issue":"8","key":"5898_CR17","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.numecd.2022.04.013","volume":"32","author":"SS Kwon","year":"2022","unstructured":"Kwon SS et al (2022) Neutrophil-lymphocyte ratio and carotid plaque burden in patients with essential thrombocythemia and polycythemia vera. Nutr Metab Cardiovasc Dis 32(8):1913\u20131916. https:\/\/doi.org\/10.1016\/j.numecd.2022.04.013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"5898_CR18","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, France"},{"issue":"446","key":"5898_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496\u2013509. https:\/\/doi.org\/10.1080\/01621459.1999.10474144","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"5898_CR20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","volume":"126","author":"T Barbui","year":"2015","unstructured":"Barbui T et al (2015) White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood 126(4):560\u2013561. https:\/\/doi.org\/10.1182\/blood-2015-04-638593","journal-title":"Blood"},{"issue":"10","key":"5898_CR21","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1038\/s41375-021-01391-2","volume":"35","author":"S Brkic","year":"2021","unstructured":"Brkic S et al (2021) Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia 35(10):2875\u20132884. https:\/\/doi.org\/10.1038\/s41375-021-01391-2","journal-title":"Leukemia"},{"issue":"3","key":"5898_CR22","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1365-2141.2010.08249.x","volume":"150","author":"S Oku","year":"2010","unstructured":"Oku S et al (2010) JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation. Br J Haematol 150(3):334\u2013344. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08249.x","journal-title":"Br J Haematol"},{"issue":"9","key":"5898_CR23","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","volume":"21","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM et al (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21(9):1952\u20131959. https:\/\/doi.org\/10.1038\/sj.leu.2404854","journal-title":"Leukemia"},{"issue":"16","key":"5898_CR24","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1182\/blood.2022017697","volume":"141","author":"AR Moliterno","year":"2023","unstructured":"Moliterno AR, Kaizer H, Reeves BN (2023) JAK2 V617F allele burden in polycythemia vera: burden of proof. Blood 141(16):1934\u20131942. https:\/\/doi.org\/10.1182\/blood.2022017697","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1007\/s00277-024-05940-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05898-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05898-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05898-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T09:18:00Z","timestamp":1724836680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05898-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["5898"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05898-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00277-024-05940-4","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"9 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-024-05940-4","URL":"https:\/\/doi.org\/10.1007\/s00277-024-05940-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical approval for this study was granted by the Mie University Hospital Ethical Committee (approval number H2022-165).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study is retrospective in nature; therefore, the requirement for informed consent was waived by the ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Keiki Nagaharu reports research funds under Takeda Pharmaceutical internationals Yoko Edahiro reports research funds under contract from Meiji Seika Pharma, and an endowed chair funded by PharmaEssentia Japan K.K. Yoshinori Hashimoto reports honoraria from Takeda Pharmaceutical and Novartis Pharmaceutical, and an endowed chair funded by PharmaEssentia Japan K.K. Tomoki Ito reports honoraria from Novartis Pharmaceutical, Sanofi, and Takeda Pharmaceutical, and honoraria and grants from Abbvie Inc. and Bristol-Meyer Squib. Akihiko Gotoh reports honoraria from Novartis Pharma K.K., Alexion Pharmaceuticals, Inc., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Nihon Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Sanofi K.K., PharmaEssentia Japan K.K. Mika Nakamae reports research fund from Veritas Corporation, honoraria to her spouse from Amgen Inc., Astellas Pharma, AstraZeneca plc., Bristol-Meyer Squib, Daiichi Sankyo, Janssen Pharmaceutical K.K., Meiji Seika Pharma Co., Ltd., Nippon Shinyaku, Novartis Pharmaceutical, Ono Pharmaceutical, Otsuka Pharmaceutical, Sumitomo Pharma, and Takeda Pharmaceutical. Fumihiko Kimura reports grants from Ono Pharmaceutical and Takeda Pharmaceutical. Keita Kirito reports honoraria from Novartis Pharmaceutical, Takeda Pharmaceutical and PharmaEssentia JAPAN. Hideho Wada reports grants from Chugai Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical, and Takeda Pharmaceutical. Kensuke Usuki reports research funds under contract from Abbvie Inc., Amgen Astellas BioPharma, Apellis Pharmaceutical, Astellas Pharma, Bristol-Meyer Squib, Daiichi Sankyo, Janssen Pharmaceutical, Nippon Shinyaku Pharmaceutical, Otsuka Pharmaceutical, SymBio Pharmaceutical, and Takeda Pharmaceutical, and honoraria and research funds under contract from Novartis Pharmaceutical. Takehiko Mori reports honoraria from Pfizer, Novartis Pharmaceutical, Takeda Pharmaceutical, PharmaEssentia Japan, and research funds under contract from Asahi Kasei Pharma, Chugai Pharmaceutical, Kyowa Kirin, Eisai Pharmaceutical, JCR Pharmaceuticals, Abbvie Inc., Sumitomo Pharma, CSL Behring, Japan Blood Products Organization and Otsuka Pharmaceutical. Kazuya Shimoda reports honoraria from Bristol-Meyer Squib, Celgene, Novartis Pharmaceutical, and Takeda Pharmaceutical, research funds under contract from PharmaEssentia Japan K.K., and grants from Abbvie Inc., Astellas Pharma, Chugai Pharmaceutical, Kyowa Kirin, and MSD. Akihiro Tomita reports honoraria from Takeda Pharmaceutical; research funds under contract from Kyowa Kirin, Novartis Pharmaceutical, Ono Pharmaceutical, Perseus Proteomics Inc., Pfizer, and Taiho Pharmaceutical; and honoraria and research funds under contract from Chugai Pharmaceutical. Koichi Akashi reports honoraria from Celgene and Novartis Pharmaceutical, grants from Asahi Kasei Pharma, Mochida, MSD, Mundi Pharma, Nippon Shinyaku Pharmaceutical, Ono Pharmaceutical, Shionogi, Sanofi, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Toyama Chemical, Shin Nippon Biomedical Laboratories, Yakult Honsha, and Takeda Pharmaceutical, honoraria and research funds under contract from Bristol-Meyer Squib and Janssen Pharmaceutical, honoraria and grants from Abbvie Inc., Chugai Pharmaceutical, and Eisai Pharmaceutical, research funds under contract and grants from Daiichi Sankyo and Otsuka Pharmaceutical, honoraria, research funds under contract, and grants from Astellas Pharma and Kyowa Kirin. Itaru Matsumura received speakers bureau fees from Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Chugai Pharmaceutical Co., Ltd., AbbVie G.K., Janssen Pharmaceutical K.K., Bristol Myers Squibb K.K. (Celgene K.K.), AstraZeneca K.K., and Otsuka Pharmaceutical Co., Ltd.; received research funding from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd.,Asahi Kasei Pharma Corp, AbbVie G.K., Taiho Pharmaceutical Co., Ltd., and received consultancy fees from Otsuka Pharmaceutical Co., Ltd.Katsuto Takenaka reports honoraria from Novartis Pharmaceutical and MSD, grants from Astellas Pharma, Chugai Pharmaceutical, and Otsuka Pharmaceutical, honoraria, and grants from Kyowa Kirin. Norio Komatsu reports honoraria from Abbvie Inc., Celgene, and Japan Tobacco Inc., research funds under contract from FUJIFILM Wako Chemicals, Fuso-pharm, Meiji Seika Pharma, Perseus Proteomics Inc., and Pfizer, grants from Bristol-Meyer Squib, Chugai Pharmaceutical, Kyowa Kirin, and Sumitomo Dainippon Pharma, honoraria and grants from Novartis Pharmaceutical and Otsuka Pharmaceutical, honoraria, research funds under contract, and grants from Takeda Pharmaceutical, honoraria, research funds under contract, and an endowed chair funded by PharmaEssentia Japan K.K. The other authors declare no conflicts of interest. Kohishi Ohishi reports research funds under contract from PharmaEssentia Japan K.K., Abbvie Inc. Isao Tawara reports honoraria from Novartis Pharmaceutical, Sanofi, and Takeda Pharmaceutical, and honoraria and grants from Abbvie Inc. and Bristol-Meyer Squib.Yuka Sugimoto reports honoraria from PharmaEssentia Japan K.K. and Novartis Pharmaceutical and research funds under contract from Incyte Biosciences, Japan and Toyo Kohan K.K.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}